Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Table 4 Baseline features of the participants

Trials	Mean age (y)	Males (%)	HbA1c (%)	Duration (y)	BMI (kg/m²)
	100/300 mg	100/300 mg	100/300 mg	100/300 mg	100/300 mg
Blonde 2016 [9]	56.4/55.8	52.2/49.7	7.8/7.8	6.5/6.7	31.0/31.2
Forst 2014 [10]	56.7/57.0	68.1/55.3	8.0/7.9	10.5/11.0	32.3/32.8
Neal 2015 [11]	62.0/63.0	67.0/65.0	8.3/8.3	16.4/16.3	33.0/33.3
Gonzalez 2013 [12]	55.5/55.3	47.3/45.0	7.9/7.9	6.7/7.1	32.4/31.4
Inagaki 2013 [13]	57.7/57.1	70.3/73.3	8.05/8.17	-	25.6/25.9
Stenlof 2013 [15]	55.1/55.3	41.5/45.2	8.1/8.0	4.5/4.3	31.3/31.7
Wilding 2013 [16]	57.4/56.1	48.4/55.8	8.1/8.1	9.0/9.4	33.3/33.2
Yale 2013 [17]	69.5/67.9	64.4/53.9	7.9/8.0	15.6/17.0	32.4/33.4
Rosenstock 2012 [18]	51.7/52.3	56.0/56.0	7.8/7.7	6.1/5.9	31.7/31.6

Abbreviations: y year, HbA1c glycosylated hemoglobin, BMI body mass index, Duration referred to duration of type 2 diabetes mellitus
100 and 300 mg were referred to canagliflozin dosage

ISSN: 2050-6511